Compass Therapeutics's three largest insider shareholders as of March 23, 2026 are Thomas J. Schuetz (Chief Executive Officer, 6.60Mn shares), Vered Bisker-Leib (Chief Executive Officer, 3.12Mn shares), Miranda Jayne Toledano (Director, 1.79Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Thomas J. Schuetz | Chief Executive Officer | 6,603,336 | 0 | 10 Feb, 2026 |
| Vered Bisker-Leib | Chief Executive Officer | 3,124,426 | 0 | 09 Feb, 2024 |
| Miranda Jayne Toledano | 1,791,549 | 0 | 29 Jun, 2021 | |
| Barry Shin | Cfo | 525,000 | 0 | 05 Jan, 2026 |
| Neil Lerner | Chief Accounting Officer | 382,500 | 0 | 05 Jan, 2026 |
| Jonathan Anderman | General Counsel | 171,000 | 0 | 05 Jan, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 08 Feb, 2026 | Thomas J. Schuetz | Common Stock | D | 36,687 | $6.52 | 6,603,336 | D | F |
| 09 Jan, 2026 | Thomas J. Schuetz | Common Stock | D | 46,777 | $5.35 | 6,640,023 | D | F |
| 02 Jan, 2026 | Thomas J. Schuetz | Common Stock | A | 250,000 | $5.17 | 6,686,800 | D | A |
| 02 Jan, 2026 | Barry Shin | Common Stock | A | 125,000 | $5.17 | 525,000 | D | A |
| 02 Jan, 2026 | James P Boylan | Stock Option (Right to Buy) | A | 90,000 | $0.00 | 90,000 | D | A |
| 02 Jan, 2026 | Philip Ferneau | Stock Option (Right to Buy) | A | 90,000 | $0.00 | 90,000 | D | A |
| 02 Jan, 2026 | Arjun Prasad | STOCK OPTION (RIGHT TO BUY) | A | 1,000,000 | $0.00 | 1,000,000 | D | A |
| 02 Jan, 2026 | Neil Lerner | Common Stock | A | 62,500 | $5.17 | 382,500 | D | A |
| 02 Jan, 2026 | Cynthia Sirard | STOCK OPTION (RIGHT TO BUY) | A | 1,000,000 | $0.00 | 1,000,000 | D | A |
| 02 Jan, 2026 | Richard S Lindahl | Stock Option (Right to Buy) | A | 90,000 | $0.00 | 90,000 | D | A |
| 02 Jan, 2026 | Mary Ann Gray | Stock Option (Right to Buy) | A | 90,000 | $0.00 | 90,000 | D | A |
| 02 Jan, 2026 | Jonathan Anderman | Common Stock | A | 150,000 | $5.17 | 171,000 | D | A |
| 02 Jan, 2026 | Carl L Gordon | Stock Option (Right to Buy) | A | 90,000 | $0.00 | 90,000 | D | A |
| 02 Jan, 2026 | Jonathan Anderman | Stock Option (Right to Buy) | A | 720,000 | $0.00 | 720,000 | D | A |
| 02 Jan, 2026 | Neil Lerner | Stock Option (Right to Buy) | A | 435,000 | $0.00 | 435,000 | D | A |
| 02 Jan, 2026 | Thomas J. Schuetz | Stock Option (Right to Buy) | A | 2,000,000 | $0.00 | 2,000,000 | D | A |
| 02 Jan, 2026 | Barry Shin | Stock Option (Right to Buy) | A | 670,000 | $0.00 | 670,000 | D | A |
| 16 Nov, 2025 | Thomas J. Schuetz | Common Stock | D | 44,025 | $4.83 | 6,436,800 | D | F |
| 27 May, 2025 | Thomas J. Schuetz | Common Stock | A | 10,000 | $2.11 | 6,480,825 | D | P |
| 09 Apr, 2025 | Carl L Gordon | Common Stock | D | 3,571,428 | $1.59 | 0 | I | S |